Together for Short Lives
Call the Helpline 0808 8088 100

Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960-1999 and registered in the Italian Off-Therapy Registry

Journal title
European journal of cancer (Oxford, England : 1990)
Publication year
Bagnasco, F.; Caruso, S.; Andreano, A.; Valsecchi, M. G.; Jankovic, M.; Biondi, A.; Miligi, L.; Casella, C.; Terenziani, M.; Massimino, M.; Sacerdote, C.; Morsellino, V.; Erminio, G.; Garaventa, A.; Faraci, M.; Micalizzi, C.; Garre, M. L.; Pillon, M.; Basso, G.; Biasin, E.; Fagioli, F.; Rondelli, R.; Pession, A.; Locatelli, F.; Santoro, N.; Indolfi, P.; Palumbo, G.; Russo, G.; Verzegnassi, F.; Favre, C.; Zecca, M.; Mura, R.; D'Angelo, P.; Cano, C.; Byrne, J.; Haupt, R.

INTRODUCTION: Advances in paediatric oncology led to the increase in long-term survival, revealing the burden of therapy-related long-term side effects. We evaluated overall and cause-specific mortality in a large cohort of Italian childhood cancer survivors (CCSs) and adolescent cancer survivors identified through the off-therapy registry. MATERIALS AND METHODS: CCSs alive 5 years after cancer diagnosis occurring between 1960 and 1999 were eligible; the last follow-up was between 2011 and 2014. Outcomes were reported as standardised mortality ratios (SMRs) and absolute excess risks (AERs). RESULTS: Among 12,214 CCSs, 1113 (9.1%) deaths occurred. Survival at 35 years since diagnosis was 87% (95% confidence interval [CI]: 86-88) and at 45 years was 81% (95% CI: 77-84). CCSs had an 11-fold increased risk of death (SMR 95% CI: 10.7-12), corresponding to an AER of 48 (95% CI: 45-51). Mortality decreased by 60% for survivors treated most recently (1990-1999). The most frequent causes of death were recurrence of the original cancer (56%), a subsequent neoplasm (19%) and cardiovascular diseases (5.8%). Among those who survived at least 15 years after diagnosis, a secondary malignancy was the leading cause of death. CONCLUSIONS: This study confirms the impact of recent advances in anticancer therapy in reducing mortality, mainly attributable to recurrence but also to other causes. However, overall mortality continues to be higher than in the general population. A long-term follow-up is needed to prevent late mortality due to secondary neoplasms and non-neoplastic causes in CCSs.

Research abstracts